What is the recommended treatment for bacteremia?

Treatment of Bacteremia

For bacteremia, immediate empiric IV antibiotic therapy targeting both MRSA and gram-negative organisms should be initiated, with definitive treatment guided by culture results and source control measures.

Initial Empiric Therapy

Start broad-spectrum IV antibiotics immediately upon suspicion of bacteremia, before culture results are available:

• For MRSA coverage: Vancomycin or daptomycin 6 mg/kg IV once daily
• For gram-negative coverage: Add appropriate agent based on local resistance patterns and suspected source

The empiric approach is critical because delayed appropriate antibiotic therapy is associated with increased mortality, particularly in severe presentations.

Definitive Therapy Based on Organism

MRSA Bacteremia

Uncomplicated bacteremia (no endocarditis, no prostheses, blood cultures clear within 2-4 days, fever resolves within 72 hours, no metastatic infection):

• Vancomycin OR daptomycin 6 mg/kg IV once daily for at least 2 weeks 1, 2
• Some experts recommend higher daptomycin doses (8-10 mg/kg) for improved outcomes 1, 2

Complicated bacteremia (persistent bacteremia, metastatic foci, or endocarditis):

• 4-6 weeks of therapy depending on infection extent 1, 2
• For endocarditis: 6 weeks of IV vancomycin or daptomycin 1, 2

Critical management points:

• Do NOT add gentamicin or rifampin to vancomycin for bacteremia or native valve endocarditis—these combinations do not improve outcomes and increase toxicity 1, 2, 1
• Obtain repeat blood cultures 2-4 days after initial positive cultures to document clearance 1, 2, 1
• All adults with MRSA bacteremia require echocardiography; transesophageal echocardiography (TEE) is preferred over transthoracic (TTE) 2

MSSA Bacteremia

Once susceptibility confirms methicillin-susceptible S. aureus:

• Switch to cefazolin or antistaphylococcal penicillin (nafcillin, oxacillin) 3
• These beta-lactams are superior to vancomycin for MSSA 2
• Duration follows same principles as MRSA (2 weeks uncomplicated, 4-6 weeks complicated)

Recent data support cefazolin as effective and safer than antistaphylococcal penicillins, despite theoretical concerns about the cefazolin inoculum effect 4.

Enterococcal Bacteremia

• Ampicillin is first-line for susceptible strains; vancomycin for ampicillin-resistant isolates 5
• 7-14 days for uncomplicated catheter-related bloodstream infection 5
• Combination therapy (cell wall agent + aminoglycoside) role is unresolved for bacteremia without endocarditis 5
• TEE indicated if: new murmur, embolic phenomena, persistent bacteremia/fever >72 hours, prosthetic valve present 5

Gram-Negative Bacteremia

For Enterobacterales (E. coli, Klebsiella, Proteus) from urinary source:

• Initial IV therapy followed by oral step-down is appropriate 6
• Oral options include fluoroquinolones, trimethoprim-sulfamethoxazole, or beta-lactams based on susceptibilities 6, 7
• No significant mortality difference between oral antibiotic classes when used as step-down therapy 6, 7

Duration of Therapy

Recent evidence challenges traditional 14-day minimum treatment:

• Meta-analysis of 4,790 patients found 7 days versus 14 days of antibiotics showed no difference in 90-day mortality (13.3% vs 14.3%), recurrence, or adverse events 8
• For uncomplicated S. aureus bacteremia specifically, shorter courses (<14 days) may be considered in carefully selected low-risk patients 9

However, the IDSA guidelines still recommend:

• Minimum 2 weeks for uncomplicated bacteremia 1, 2
• 4-6 weeks for complicated cases 1, 2

Given the high mortality (15-30%) and metastatic infection risk (>33%) with S. aureus bacteremia 3, err on the side of longer treatment when clinical uncertainty exists.

Essential Source Control Measures

Source identification and elimination is as critical as antibiotics 1, 2:

• Remove infected intravascular catheters, implanted devices
• Drain abscesses
• Surgically debride infected tissue
• Perform imaging (CT, MRI) based on symptoms to identify metastatic foci

Failure to remove infected devices is associated with higher relapse and mortality 2.

Pediatric Considerations

• IV vancomycin 15 mg/kg every 6 hours is recommended 1, 2
• Clindamycin 10-13 mg/kg every 6-8 hours can be used if clindamycin resistance <10% and patient is stable 1
• Linezolid is an alternative: 600 mg twice daily for >12 years; 10 mg/kg every 8 hours for <12 years 1
• TTE likely adequate in young children; TEE reserved for those with congenital heart disease or bacteremia >2-3 days 2

Common Pitfalls to Avoid

1. Do not delay antibiotics while awaiting cultures—empiric therapy saves lives
2. Do not use combination therapy (vancomycin + gentamicin or rifampin) for MRSA bacteremia—no benefit, increased toxicity
3. Do not skip echocardiography in S. aureus bacteremia—endocarditis occurs in ~12% of cases
4. Do not continue vancomycin for MSSA—switch to beta-lactam for superior outcomes
5. Do not forget source control—antibiotics alone are insufficient without removing infected hardware or draining collections